What if lowering your cholesterol did not mean taking a pill every day for the rest of your life, but a single treatment that rewrites one instruction in your liver? A first-in-human trial led by Cleveland Clinic has just shown that this idea holds up, at least for one year and in a small group of patients.

The headline result

In this Phase 1 trial, 15 people with lipid disorders that did not respond well to standard medication received a one-time infusion of an experimental CRISPR-Cas9 gene-editing therapy called CTX310. The researchers had already reported encouraging results two months after treatment. The new question was simple: do the effects last?

They do, so far. Twelve months after treatment, participants who received the highest dose showed:

  • 52.5% lower LDL (“bad”) cholesterol compared with baseline
  • 47.8% lower triglycerides compared with baseline
  • No serious adverse events related to the therapy during the one-year follow-up

How does CTX310 work?

CRISPR-Cas9 is a gene-editing tool that can be directed to a specific stretch of DNA to change it. CTX310 delivers the editing machinery, packaged in tiny lipid nanoparticles, through a single intravenous infusion. The particles travel to the liver, where the editing takes place directly inside the body’s own cells.

The target is a gene called ANGPTL3. When this gene is switched off, the liver produces less of a protein that helps regulate blood fats, and both LDL cholesterol and triglycerides fall. The logic comes from nature: people who are born with naturally inactive versions of this gene tend to have lower lipid levels and a lower risk of coronary artery disease. CTX310 is an attempt to reproduce that protective genetic profile in people who were not born with it.

Doses in the trial ranged from 0.1 to 0.8 mg/kg, and participants were pre-treated with corticosteroids and antihistamines to reduce the risk of infusion reactions. At the highest dose, both LDL cholesterol and triglycerides dropped by roughly 50% on average after a year.

Why durability matters

Statins and other lipid-lowering drugs work well, but they only work while you keep taking them, and many people stop within the first year. A therapy that edits the gene once would change that equation completely, because there would be nothing to forget, skip or run out of. That is why a result at 12 months is more meaningful than one at two months: it is the first sign that the edit is stable and the effect is not fading.

“The durability of the lipid-lowering effect was impressive.” Dr. Luke Laffin, Cleveland Clinic cardiologist and first author of the study

What this does not tell us yet

It is worth keeping the excitement in proportion:

  • The trial is small. Fifteen participants took part across several dose groups, so only a handful received the highest dose.
  • One year is short for a permanent edit. Because gene editing cannot be undone, the FDA recommends long-term safety monitoring, and this study plans follow-up for the next 15 years.
  • Lower lipids are not the same as fewer heart attacks. Phase 1 trials test safety and biological effect; they are not designed to show that the therapy prevents cardiovascular events.
  • Funding and disclosure. The study was funded by CRISPR Therapeutics AG, and Dr. Laffin’s institution has received research funding from the company.

What comes next

The results were presented at the 2026 European Society of Cardiology annual meeting and published at the same time in the New England Journal of Medicine. The researchers say they want to study the therapy in a larger number of patients, and CRISPR Therapeutics is advancing CTX310 into a Phase 1b trial. If the safety and durability hold up in bigger and longer studies, one-time gene editing could become a new way to think about preventing heart disease.

Sources

  • Original paper: Laffin LJ, Nicholls SJ, et al. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. New England Journal of Medicine, August 28, 2026. DOI: 10.1056/NEJMc2609825. Read the paper
  • Press release: Cleveland Clinic, First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year, August 28, 2026. Read the press release
  • Press release: CRISPR Therapeutics, Phase 1a Data for CTX310 at ESC Congress 2026. Read the press release